Fig. 2: Multi-scale modelling of mutations in subsets of DLBCL and Multiple Myeloma recapitulates clinical trial data. | Blood Cancer Journal

Fig. 2: Multi-scale modelling of mutations in subsets of DLBCL and Multiple Myeloma recapitulates clinical trial data.

From: Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data

Fig. 2

A (left) Simplified schematic model divided into component signalling pathways featuring NF-κB signalling, apoptosis, the cell cycle and differentiation (adapted from ref. 11), full details provided in Supplementary Material. A (right) Schematic representation of the progression of cell lineages over time during multiscale simulations. The example depicts a mutation that allows cells to continue to proliferate when they would otherwise die. B, C Simulated cell population size (cell count) over time for wild-type (blue), individual mutations (orange and red) and double hits where both mutations are combined (green). D Overall survival (OS) data for groups of patients with MYC and BCL2/BCL6 mutations. E Cell population size (cell count) over time for simulations of gain1q multiple myeloma. CKS1B and MCL1 are located on chromosome 1q and therefore amplifications in this chromosome increase the abundance of both of these genes. F Progression-free survival (PFS) data for groups of patients with upregulation of CKS1B and MCL1 due to 2, 3 or 4 or more copies of chromosome 1q. NR not reached.

Back to article page